Stocks to buy in 2026 for long term: Dr Lal PathLabs, IDFC First Bank among 5 stocks that could give 10-30% return - Brokerage Recommendations

Brokerage consensus reflects constructive positioning across select Indian equities, with healthcare and banking sectors anchoring near-term momentum. The recommendation cluster—spanning diagnostics, specialty banking, and pharma—signals analyst confidence in earnings visibility through 2026, though the 10-30% return guidance suggests moderate conviction rather than conviction-driven upgrades. This represents typical year-end tactical rebalancing.

FRBA (IDFC First Bank) appears prominently in the financial services cohort, indicating brokerages expect margin expansion and credit growth acceleration. Banking sector strength depends on sustained economic growth and benign asset quality trends; any deterioration in loan books would reverse bullish stances. Dr Lal PathLabs positioning in healthcare reflects confidence in diagnostics volume recovery post-pandemic normalization.

The diversification across healthcare, pharmaceuticals, and specialty chemicals suggests brokerages are hedging against sector-specific headwinds by building multi-leg portfolios. Defence and pharma inclusions indicate emerging geopolitical and export competitiveness themes, though these remain secondary to earnings-driven narratives. Currency volatility and global demand cycles present asymmetric downside risks.

Sector implication: Indian brokerage optimism on select stocks reflects macro recovery expectations rather than structural bull markets. The consensus targets remain anchored to 2-3 year earnings CAGR assumptions; execution risk is material, particularly in banking (NPA cycles) and pharma (pricing pressures). This recommendation set is defensive-leaning positioning relative to broader market volatility.